Literature DB >> 15362573

A novel susceptibility locus for moyamoya disease on chromosome 8q23.

Kaoru Sakurai1, Yasue Horiuchi, Hidetoshi Ikeda, Kiyonobu Ikezaki, Takashi Yoshimoto, Masashi Fukui, Tadao Arinami.   

Abstract

Moyamoya disease (MIM 252350) is characterized by stenosis or occlusion of the terminal portions of the bilateral internal carotid arteries and by abnormal vascular networks at the base of the brain. There is a high incidence of moyamoya disease in Asia, especially in Japan. Multifactorial inheritance is estimated with lambda(s)>40. Previous linkage studies have indicated that susceptibility loci for the disease are located on chromosomes 3p, 6q, and 17q. In the present study, we searched for loci linked to the disease in 12 Japanese families using 428 microsatellite markers and found significant evidence for linkage to 8q23 [maximum LOD score (MLS) of 3.6] and suggestive evidence for linkage to 12p12 (MLS=2.3). The present study revealed a novel locus for moyamoya disease.

Entities:  

Mesh:

Year:  2004        PMID: 15362573     DOI: 10.1007/s10038-004-0143-6

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  12 in total

1.  Linkage analysis of moyamoya disease on chromosome 6.

Authors:  T K Inoue; K Ikezaki; T Sasazuki; T Matsushima; M Fukui
Journal:  J Child Neurol       Date:  2000-03       Impact factor: 1.987

Review 2.  Moyamoya disease.

Authors:  M Fukui; S Kono; K Sueishi; K Ikezaki
Journal:  Neuropathology       Date:  2000-09       Impact factor: 1.906

3.  Worldwide distribution of moyamoya disease.

Authors:  Y Goto; Y Yonekawa
Journal:  Neurol Med Chir (Tokyo)       Date:  1992-11       Impact factor: 1.742

4.  Parametric and nonparametric linkage analysis: a unified multipoint approach.

Authors:  L Kruglyak; M J Daly; M P Reeve-Daly; E S Lander
Journal:  Am J Hum Genet       Date:  1996-06       Impact factor: 11.025

5.  Allele-sharing models: LOD scores and accurate linkage tests.

Authors:  A Kong; N J Cox
Journal:  Am J Hum Genet       Date:  1997-11       Impact factor: 11.025

6.  Epidemiological features of moyamoya disease in Japan: findings from a nationwide survey.

Authors:  K Wakai; A Tamakoshi; K Ikezaki; M Fukui; T Kawamura; R Aoki; M Kojima; Y Lin; Y Ohno
Journal:  Clin Neurol Neurosurg       Date:  1997-10       Impact factor: 1.876

7.  Familial occurrence of moyamoya disease.

Authors:  T Yamauchi; K Houkin; M Tada; H Abe
Journal:  Clin Neurol Neurosurg       Date:  1997-10       Impact factor: 1.876

8.  Linkage of familial moyamoya disease (spontaneous occlusion of the circle of Willis) to chromosome 17q25.

Authors:  T Yamauchi; M Tada; K Houkin; T Tanaka; Y Nakamura; S Kuroda; H Abe; T Inoue; K Ikezaki; T Matsushima; M Fukui
Journal:  Stroke       Date:  2000-04       Impact factor: 7.914

9.  Mapping of a familial moyamoya disease gene to chromosome 3p24.2-p26.

Authors:  H Ikeda; T Sasaki; T Yoshimoto; M Fukui; T Arinami
Journal:  Am J Hum Genet       Date:  1999-02       Impact factor: 11.025

10.  Role of transforming growth factor-beta1 in the pathogenesis of moyamoya disease.

Authors:  M Hojo; M Hoshimaru; S Miyamoto; W Taki; I Nagata; M Asahi; N Matsuura; R Ishizaki; H Kikuchi; N Hashimoto
Journal:  J Neurosurg       Date:  1998-10       Impact factor: 5.115

View more
  47 in total

1.  Comparative analysis of serum proteomes of moyamoya disease and normal controls.

Authors:  Eun-Jeong Koh; Han-Na Kim; Tian-Ze Ma; Ha-Young Choi; Yong-Geun Kwak
Journal:  J Korean Neurosurg Soc       Date:  2010-07-31

2.  P.R4810K, a polymorphism of RNF213, the susceptibility gene for moyamoya disease, is associated with blood pressure.

Authors:  Akio Koizumi; Hatasu Kobayashi; Wanyang Liu; Yukiko Fujii; S T M L D Senevirathna; Shanika Nanayakkara; Hiroko Okuda; Toshiaki Hitomi; Kouji H Harada; Katsunobu Takenaka; Takao Watanabe; Shinichiro Shimbo
Journal:  Environ Health Prev Med       Date:  2012-08-10       Impact factor: 3.674

Review 3.  Cerebrovascular disorders associated with genetic lesions.

Authors:  Philipp Karschnia; Sayoko Nishimura; Angeliki Louvi
Journal:  Cell Mol Life Sci       Date:  2018-10-16       Impact factor: 9.261

4.  Moyamoya complicated by thrombotic cerebrovascular accident in a Caucasian woman with collagenous colitis.

Authors:  Manshi Valluri; Hossein Akhondi; Mark Hyndman
Journal:  Neurol Sci       Date:  2018-08-09       Impact factor: 3.307

Review 5.  Inherited neurovascular diseases affecting cerebral blood vessels and smooth muscle.

Authors:  Christine Sam; Fei-Feng Li; Shu-Lin Liu
Journal:  Metab Brain Dis       Date:  2015-04-21       Impact factor: 3.584

6.  Inheritance pattern of familial moyamoya disease: autosomal dominant mode and genomic imprinting.

Authors:  Y Mineharu; K Takenaka; H Yamakawa; K Inoue; H Ikeda; K-I Kikuta; Y Takagi; K Nozaki; N Hashimoto; A Koizumi
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-06-20       Impact factor: 10.154

7.  Moyamoya disease and surgical intervention.

Authors:  Jay W Rhee; Suresh N Magge
Journal:  Curr Neurol Neurosci Rep       Date:  2011-04       Impact factor: 5.081

8.  The roles of methylenetetrahydrofolate reductase 677C>T and 1298A>C polymorphisms in moyamoya disease patients.

Authors:  Young Seok Park; Young Joo Jeon; Hyun Seok Kim; In Bo Han; Joong-Uhn Choi; Dong-Seok Kim; Nam Keun Kim
Journal:  Childs Nerv Syst       Date:  2014-08-07       Impact factor: 1.475

9.  Identification of novel biomarker candidates by proteomic analysis of cerebrospinal fluid from patients with moyamoya disease using SELDI-TOF-MS.

Authors:  Yoshio Araki; Kazuhiro Yoshikawa; Sho Okamoto; Masaki Sumitomo; Mikio Maruwaka; Toshihiko Wakabayashi
Journal:  BMC Neurol       Date:  2010-11-08       Impact factor: 2.474

10.  Pituitary stalk duplication in association with moya moya disease and bilateral morning glory disc anomaly - broadening the clinical spectrum of midline defects.

Authors:  T Loddenkemper; N R Friedman; P M Ruggieri; A Marcotty; J Sears; E I Traboulsi
Journal:  J Neurol       Date:  2008-03-20       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.